Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 5/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579005 | 0.92 | FFAR2 (0.36) | FFAR2TLR9TLR8TLR7 | |
| SCHEMBL3586340 | 0.85 | NAMPT (0.35) | FFAR2PTGDR2TLR8TLR7 | |
| SCHEMBL3592689 | 0.85 | NAMPT (0.34) | FFAR2PTGDR2TLR9TLR8TLR7 | |
| SCHEMBL3585214 | 0.84 | FFAR2 (0.34) | FFAR2TLR9TLR8TLR7 | |
| SCHEMBL3578424 | 0.84 | LIPE (0.42) | — | |
| SCHEMBL3579136 | 0.83 | MAP2 (0.34) | FFAR2PTGDR2 | |
| SCHEMBL3582755 | 0.81 | HTR6 (0.33) | FFAR2TLR9TLR8TLR7 | |
| SCHEMBL3574231 | 0.81 | CRHBP (0.40) | FFAR2 | |
| SCHEMBL3582278 | 0.81 | LIMK2 (0.40) | TLR9TLR8TLR7 | |
| SCHEMBL3583691 | 0.81 | NAMPT (0.33) | FFAR2TLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113421-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-05-06 | — | — | US | claimed |
| US-20100113421-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113421-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | RTF1, RNGTT, POLR2E | FFAR2 4589/4885PTGDR2 3924/4885TLR9 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.